Table 3.
Data from national registries.
| Outcomes | Type of data | Registry | Time period |
|---|---|---|---|
| Primary outcome | Redeemed prednisolone prescriptions including time of redemption, dosage, number of packages, number of tablets | Danish National Prescription Registry | From index date* to death, emigration, or end of follow-up |
| Secondary outcomes | Aortic aneurysm, dissections, peripheral artery disease, aortic surgery, amputation | Danish National Patient Registry (DNPR) | From 5 years before the index date to death, emigration, or end of follow-up |
| The Danish Cause of Death Registry | Index date to death | ||
| Exploratory | Vascular complications: Aortic aneurysm, dissections, peripheral artery disease, aortic surgery, amputation, blindness, low vision, visual disturbances, acute myocardial infarction, ischemic stroke, percutaneous coronary intervention (PCI), and coronary artery bypass grafting | Danish National Patient Registry (DNPR) | From 5 years before the index date to death, emigration, or end of follow-up |
| The Danish Cause of Death Registry | Index date to death | ||
| Safety: Osteoporosis and osteoporotic events, infections, hypertension, myopathy, adrenal insufficiency, psychosis, gastrointestinal perforation, peptic ulcer, avascular necrosis, cataract, glaucoma | Danish National Patient Registry (DNPR) | From 5 years before index date* to death, emigration, or end of follow-up** | |
| Cause of death | The Danish Cause of Death Registry | Index date to death | |
| Covariates | Diagnoses contained in the Charlson Comorbidity Index** | Danish National Patient Registry (DNPR) | From 5 years before the index date to death, emigration, or end of follow-up |
| HbA1c and cholesterol (total, LDL, HDL, and triglycerides) | The Registry of Laboratory Results for Research | From 5 years before the index date to death, emigration, or end of follow-up | |
| Follow-up time estimation | Death and emigration | Danish Civil Registration System | From index date to end of follow-up |
* Index date; Date of diagnosis. **The exploratory outcomes will be evaluated after 5 years and by the end of follow-up. **Charlson comorbidity index (59): Myocardial infarction, congestive heart disease, vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, liver disease, diabetes, hemiplegia, renal disease, tumor (+/−metastatic) leukemia, lymphoma, AIDS.